Visual Particulate Inspection

Visual particulate inspection is the hundred percent examination of filled parenteral units against black and white backgrounds under defined illumination. It is explicitly probabilistic: detection probability rises with particle size, approaching certainty only for particles of a few hundred microns and falling steeply below about a hundred. Compendial language therefore asks that products be essentially free of visible particulates, with a separate test counting subvisible particles against per-container limits.

What the inspection finds tells you where a process went wrong. Fibres indicate environmental control failures, glass lamellae indicate delamination of the container under aggressive formulation chemistry, silicone droplets come from syringe lubrication, and translucent amorphous material is often protein aggregate. Particulate contamination is among the most frequent stated reasons for injectable recalls, and it matters clinically because particles can lodge in the pulmonary vasculature and aggregated protein is associated with immunogenicity.

Inspection is a detection control, not a quality-creating one, which shapes what it can prove. A unit that passes has demonstrated the absence of readily visible matter under those conditions and nothing about sterility, endotoxin, potency or subvisible burden. For a lyophilised product the inspection covers the cake and, separately, the solution after reconstitution.

The inference that does not follow is the one grey-market sellers rely on: a photograph of a clear solution offered as evidence of purity or sterility. Clarity excludes gross visible matter and nothing else, since endotoxin, degraded peptide and bacterial contamination are all invisible. In the other direction, a faint opalescence that is a documented characteristic of a formulation is sometimes mistaken for a defect.